Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02427568 · ClinicalTrials.gov registry record · Phase 2
MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness
A Phase 2 study, sponsored by Resilient Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02427568: Completed Phase 2 study, sponsored by Resilient Pharmaceuticals.
NCT02427568 is a Phase 2 study that has completed, run by Resilient Pharmaceuticals. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02427568, a Phase 2 study, has completed, sponsored by Resilient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with anxiety associated with a life-threatening illness. The main question it aims to answer is: Does anxiety decrease in people receiving two sessions of MDMA-assisted therapy? Researchers will compare people receiving placebo with therapy to people receiving MDMA-assisted therapy. * Participants will undergo three non-drug preparatory therapy sessions before their first blinded session of MDMA or placebo with therapy. * Each medication session will be followed by three non-drug integrative therapy sessions. * After the second blinded medication session, participants receiving MDMA will complete a third open-label medication session. * Participants who received placebo will be given the option to crossover and receive three sessions of assisted therapy.
Interventions
- DRUG Placebo
- BEHAVIORAL Therapy
- DRUG Midomafetamine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-05-14 |
| Est. Completion | 2018-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02427568
The ClinicalTrials.gov registry entry for NCT02427568 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Resilient Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02427568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02427568 about?
NCT02427568 is a clinical study titled "MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness". The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with anxiety associated with a life-threatening illness. The main question it aims to answer is: Does anxiety decrease in people receiving two sessions of MDMA-assisted therapy? Researchers will com...
What is the current status of trial NCT02427568?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2015-05-14. Estimated completion is 2018-05-17.
What interventions are being tested in trial NCT02427568?
The interventions under investigation include: Placebo (DRUG), Therapy (BEHAVIORAL), Midomafetamine HCl (DRUG).
Who is sponsoring clinical trial NCT02427568?
This trial is sponsored by Resilient Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.